Key Developments: Immunogen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

19.38USD
1 Aug 2013
Price Change (% chg)

$0.33 (+1.73%)
Prev Close
$19.05
Open
$19.25
Day's High
$19.44
Day's Low
$18.98
Volume
247,131
Avg. Vol
210,169
52-wk High
$19.98
52-wk Low
$10.85

Search Stocks

Latest Key Developments (Source: Significant Developments)

ImmunoGen Inc Announces FDA Acceptance of IND for Company’s Novel EGFR-Targeting ADC, IMGN289
Thursday, 1 Aug 2013 04:01pm EDT 

ImmunoGen Inc announced that the Company`s IMGN289 Investigational New Drug (IND) application has been accepted by the US FDA and is active. This enables ImmunoGen to advance IMGN289 into human clinical testing, expected to start in 4Q2013. This is the third IND for a novel, wholly owned anticancer compound to be submitted by ImmunoGen and accepted by the FDA in the past two years.  Full Article

ImmunoGen Inc Lowers FY 2013 Earnings Guidance
Friday, 26 Apr 2013 06:30am EDT 

ImmunoGen Inc announced that it now expects net loss for to be between $76 million to $80 million, its net cash used in operations to be between $65 million to $69 million for fiscal 2013. This compares with previous guidance, issued in January 2013, of a projected net loss between $70 million to $74 million, net cash used in operations of between $78 million to $82 million.  Full Article

ImmunoGen Inc Announces Preclinical Findings With IMGN289 Product Candidate For Treatment Of EGFR-Overexpressing Cancers
Wednesday, 10 Apr 2013 08:00am EDT 

ImmunoGen Inc announced preclinical data for EGFR-targeting ADC, IMGN289. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2013 in Washington, DC (abstracts# 5463, 5467, and 5483). ImmunoGen developed IMGN289 to treat EGFR-overexpressing cancers, which include many cases of squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC), and expects to begin clinical testing of the compound later this year. IMGN289 contains an EGFR-binding antibody that can achieve inhibition of EGFR-signaling, an important mechanism of action for EGFR-overexpressing cancers being fueled by EGFR. In studies reported, the antibody in IMGN289 was shown to provide potency comparable to or better than cetuximab (Erbitux) in preclinical models of SCCHN and NSCLC. The DM1 enables IMGN289 to kill EGFR-overexpressing cancers by a second method that is independent of the sensitivity of these cells to EGFR inhibition. In preclinical models of EGFR-overexpressing cancers reported, IMGN289 was active against NSCLC not dependent on EGFR signaling and against NSCLC with acquired resistance to TKIs; in SCCHN models responsive to EGFR, IMGN289 was significantly more active than cetuximab.  Full Article

ImmunoGen Inc Reaffirms FY 2013 Earnings Guidance
Friday, 25 Jan 2013 06:30am EST 

ImmunoGen Inc announced that financial guidance for fiscal 2013 remains unchanged from that issued in October 2012. The Company expects net loss for fiscal 2013 to be between $70-$74 million.  Full Article

FDA Grants Priority Review To Roche Holding AG's Breast Cancer Drug Being Developed With ImmunoGen Inc-Reuters
Tuesday, 6 Nov 2012 05:47pm EST 

Reuters reported that Roche Holding AG said U.S. health regulators granted a priority review to its experimental breast cancer drug TDM-1, expediting the review process for the marketing application of the drug. The U.S. Food and Drug Administration will announce its decision on the marketing approval by February 26. TDM-1, or trastuzumab emtansine, is being developed with ImmunoGen Inc, using ImmunoGen's targeted antibody payload delivery technology.  Full Article

ImmunoGen Inc Reaffirms FY 2012 Earnings Guidance
Friday, 26 Oct 2012 06:30am EDT 

ImmunoGen Inc announced that financial guidance for fiscal 2013 remains unchanged from that issued in August 2012. The Company expects net loss for fiscal 2013 to be between $70-$74 million. According to I/B/E/S Estimates, analysts are expecting the Company to report net income of $(73) million for fiscal 2013.  Full Article

ImmunoGen Inc Announces Trastuzumab Emtansine Significantly Improved Survival In EMILIA Phase III Trial
Monday, 27 Aug 2012 01:37am EDT 

ImmunoGen Inc announced that Roche has reported that updated results from its EMILIA Phase III trial show that patients treated with trastuzumab emtansine had a improvement in OS compared to those randomized to standard-of-care therapy. Trastuzumab emtansine utilizes ImmunoGen’s TAP technology with the trastuzumab antibody and is in global development by Roche under an agreement between ImmunoGen and Genentech, a member of the Roche Group. Also reported was that Genentech has submitted a Biologics License Application (BLA) for trastuzumab emtansine to the US FDA, and that Roche expects to soon submit a Marketing Authorization Application (MAA) to the EMA. Roche has Phase III trials underway evaluating trastuzumab emtansine both for newly diagnosed and for previously treated metastatic HER2-positive breast cancer. Additionally, it plans to initiate registration trials beginning in 2013 to evaluate the compound for three settings in earlier-stage disease: adjuvant use; neoadjuvant use; and treatment of patients with residual invasive disease following standard neoadjuvant therapy.  Full Article

ImmunoGen Inc Issues FY 2013 Net Income Guidance In Line With Analysts' Estimates
Friday, 3 Aug 2012 06:30am EDT 

ImmunoGen Inc announced that for fiscal 2013, it expects net loss for fiscal 2013 to be between $70 million to $74 million. According to I/B/E/S Estimates, analysts are expecting the Company to report net income of $(74) million for fiscal 2013.  Full Article

ImmunoGen Inc Prices Public Offering Of Common Stock
Thursday, 12 Jul 2012 09:05am EDT 

ImmunoGen, Inc. announced that it has priced an underwritten public offering of 6.25 million shares of its common stock at a price to the public of $16 per share. Gross proceeds are expected to be approximately $100 million, before deducting the underwriting discounts and commissions and offering expenses payable by ImmunoGen. The offering is expected to close on or about July 17, 2012, subject to satisfaction of customary closing conditions. ImmunoGen has granted the underwriters a thirty (30) day option to purchase up to 937,500 additional shares. Morgan Stanley & Co. LLC and Jefferies & Company, Inc. are acting as joint book-running managers for the offering and Oppenheimer & Co. Inc., RBC Capital Markets, LLC, William Blair & Company, LLC, Cowen and Company, LLC, and Summer Street Research Partners are acting as co-managers.  Full Article

ImmunoGen Inc Announces Proposed Public Offering Of Common Stock
Wednesday, 11 Jul 2012 04:01pm EDT 

ImmunoGen Inc announced that it intends to offer for sale its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Morgan Stanley & Co. LLC and Jefferies & Company, Inc. are acting as joint book-running managers for the proposed offering.  Full Article

CORRECTED-UPDATE 3-FDA approves Roche drug for late-stage breast cancer

(Corrects paragraph 5 to show control arm included Xeloda, not Herceptin)

Search Stocks